100 per cent confidence13 Mar 2025 12:39
💥💥 IMMUPHARMA – STRAP IN, THIS ROCKET’S ABOUT TO IGNITE! 💥💥
🚀 Sorry, i know you were all waiting for a formal update from me. I was busy buying ferrets at the local car boot sale.... just read the RNS, i nearly spat out my decaffe latte with soya milk (aka a 'why bother') Well this a game-changing RNS, more mouth watering than a wheatgrass & falla-fell sandwich (if you havent eaten all day) - seriously, don't blink on this news... we are off to the races, probably racing past Saturn's newly discovered moons.
Let’s slice this one up real nice and juicy:
🔬 P140’s Mechanism of Action (MOA) LOCKED IN!
Not just “we think,” not just “it looks like” – concrete, scientific PROOF. The immunomodulatory pathway has been confirmed in a world-leading US lab—we’re talking Toll-like receptor modulation with antigen-specific tolerance induction. If that doesn’t scream first-in-class, best-in-class, I dunno what does.
🔬 NON-IMMUNOSUPPRESSIVE – AKA THE HOLY GRAIL!
Every autoimmune treatment today? Either clobbers your immune system like a wrecking ball or barely moves the needle. P140? Different beast altogether. It reprograms antigen-presenting cells while preserving normal immune function. No nasty side effects, no leaving patience open to infections, just pure, targeted efficacy.
🔬 SAFE & EFFECTIVE – A MEDICAL GOLDMINE!
Safety is the Achilles' heel of most new autoimmune therapies. Not here. No systemic toxicity, no lymphocyte depletion – just clean, controlled immune recalibration. The data backs it, the science proves it, and the market is BEGGING for it.
💰 BIG PHARMA IS WATCHING – AND THEY LIKE WHAT THEY SEE!
The autoimmune market? $360 BILLION by 2030. The average licensing deal in this space? $1bn. Do you really think IMM would be talking “potential partners” in an RNS if they weren’t already deep in talks? The only thing missing is the ink drying on the contract.
💡 READ BETWEEN THE LINES You all saying, ok– THIS ISN’T JUST AN RNS, IT’S A SIGNAL!
🔹 New patents = LOCKING in exclusivity before deal time.
🔹 "Ongoing discussions with potential partners" = THEY’RE AT THE TABLE.
🔹 Data “to be released in due course” = They’re timing this for MAXIMUM IMPACT.
🚀 HISTORICAL PARALLELS – WE’VE SEEN THIS BEFORE!
When a small-cap biotech confirms a breakthrough and hints at deals, what happens next? BOOM.
🔥 Synairgen? 40x in a flash.
🔥 Avacta? 20x before you could blink.
🔥 4D Pharma? 15x before it even hit main stage.
💎 And now we’ve got IMMUPHARMA in the same position – but with stronger, more validated science! Some are suggesting 100x minimum. Whether you agree with that or not, it’s something worth thinking about.
The smart money already knows what’s coming. If you’re sitting on the sidelines waiting for the RNS that literally spells it out like “BIG PHARMA ACQUIRES P140 FOR $BILLIONS” – by then
Sign In
Follow the stocks
